Scott Alexander McDonald
Biographic Data
| ID | 10031991 |
|---|---|
| NAME | Scott Alexander McDonald |
| GIVEN NAMES | Scott Alexander |
| FAMILY NAME | McDonald |
| SIGNATURE | MCDONALD S A |
| VERIFIED | No |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 0 |
Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options
Introduction: A scaled-up treatment cascade with direct-acting antiviral (DAA) therapy is necessary to achieve global WHO targets for hepatitis C virus (HCV) elimination in Malaysia. Recently, limited access to sofosbuvir/daclatasvir (SOF/DAC) is available through compulsory licensing, with access to sofosbuvir/velpatasvir (SOF/VEL) expected through voluntary licensing due to recent agreements. SOF/VEL has superior clinical outcomes but has highe…
No prominent works on this page.
Budget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options
Introduction: A scaled-up treatment cascade with direct-acting antiviral (DAA) therapy is necessary to achieve global WHO targets for hepatitis C virus (HCV) elimination in Malaysia. Recently, limited access to sofosbuvir/daclatasvir (SOF/DAC) is available through compulsory licensing, with access to sofosbuvir/velpatasvir (SOF/VEL) expected through voluntary licensing due to recent agreements. SOF/VEL has superior clinical outcomes but has highe…
Daclatasvir (1 work) · Emergency Medicine (1 work) · Health Systems, Economic Evaluations, Quality of Life (1 work) · Hepatitis C virus (1 work) · Hepatitis C virus research (1 work) · Internal Medicine (1 work) · Liver disease (1 work) · Medicine (1 work) · Pharmaceutical Economics and Policy (1 work) · Sofosbuvir (1 work)